Algert Global LLC Cuts Position in CryoPort, Inc. $CYRX

Key Points

• Algert Global LLC significantly reduced its holdings in CryoPort, Inc. by 60.9% during the first quarter, owning only 36,411 shares worth $221,000 as of the end of the quarter.
• CryoPort reported a quarterly earnings loss of ($0.29) per share, missing the consensus estimate, but generated revenue of $45.45 million which exceeded expectations.
• Over 92.90% of CryoPort's stock is owned by institutional investors, showing strong institutional interest in the company despite recent insider selling activities.

Algert Global LLC reduced its position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 60.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,411 shares of the company's stock after selling 56,651 shares during the period. Algert Global LLC owned approximately 0.07% of CryoPort worth $221,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CYRX. Wells Fargo & Company MN raised its holdings in CryoPort by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 28,767 shares of the company's stock worth $224,000 after purchasing an additional 6,533 shares in the last quarter. Invesco Ltd. raised its holdings in CryoPort by 11.6% during the fourth quarter. Invesco Ltd. now owns 51,803 shares of the company's stock worth $403,000 after purchasing an additional 5,364 shares in the last quarter. Renaissance Technologies LLC purchased a new position in CryoPort during the fourth quarter worth about $194,000. Barclays PLC raised its holdings in CryoPort by 8.9% during the fourth quarter. Barclays PLC now owns 88,654 shares of the company's stock worth $690,000 after purchasing an additional 7,237 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in CryoPort by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock worth $6,615,000 after purchasing an additional 63,301 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CYRX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Morgan Stanley decreased their price objective on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. BTIG Research decreased their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, July 7th. Finally, KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price objective on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, CryoPort presently has a consensus rating of "Buy" and an average target price of $12.00.

CryoPort Trading Up 2.0%

NASDAQ:CYRX traded up $0.17 on Friday, reaching $8.86. The stock had a trading volume of 518,531 shares, compared to its average volume of 1,078,572. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The company has a market cap of $443.62 million, a price-to-earnings ratio of 6.66 and a beta of 1.62. The firm's fifty day moving average is $7.84 and its two-hundred day moving average is $6.71. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $9.48.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million during the quarter, compared to analysts' expectations of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Equities analysts expect that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In other CryoPort news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the sale, the chief financial officer owned 207,213 shares in the company, valued at $1,796,536.71. The trade was a 4.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total value of $352,260.00. Following the completion of the sale, the insider owned 90,411 shares of the company's stock, valued at $618,411.24. This trade represents a 36.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 492,247 shares of company stock worth $3,384,579 over the last ninety days. Insiders own 10.10% of the company's stock.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.